When developing new therapeutics and especially complex modalities, a series of challenges and risks typically arise. One such risk is unwanted immunogenicity, which can lead to decreased efficacy and safety. Click to listen to this insightful talk with our expert, Sofie Pattyn, CTO and founder of ImmunXperts, a IQVIA Laboratories Company, who discusses how today’s tools and strategies that can improve and accelerate therapeutic drug development in an early stage.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Automation within an ADME Laboratory
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
